within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD06_GlimepirideAndPioglitazone;
model GlimepirideAndPioglitazone 
   extends Pharmacolibrary.Drugs.ATC.A.A10BD06;

  annotation(Documentation(
    info ="<html><body><p>Glimepiride and pioglitazone (ATC code A10BD06) is a fixed-dose combination oral medication used in the treatment of type 2 diabetes mellitus. Glimepiride is a second-generation sulfonylurea that stimulates insulin secretion from pancreatic beta cells, and pioglitazone is a thiazolidinedione that improves insulin sensitivity in peripheral tissues. The combination is approved and in clinical use for adults with type 2 diabetes to improve glycemic control when diet, exercise, and single-agent therapy are insufficient.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for the fixed-dose combination product based on known single-agent data as there are no published compartmental pharmacokinetic studies reporting both drug models together in the fixed combination in healthy adults or patients with type 2 diabetes.</p><h4>References</h4><ol><li><p>Ni, XJ, et al., &amp; Wen, YG (2014). Simultaneous determination of glimepiride and pioglitazone in human plasma by liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic study. <i>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</i> 960 247–252. DOI:<a href=&quot;https://doi.org/10.1016/j.jchromb.2014.04.039&quot;>10.1016/j.jchromb.2014.04.039</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24835512/&quot;>https://pubmed.ncbi.nlm.nih.gov/24835512</a></p></li><li><p>Kirchheiner, J, et al., &amp; Brockmöller, J (2005). Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. <i>Clinical pharmacokinetics</i> 44(12) 1209–1225. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200544120-00002&quot;>10.2165/00003088-200544120-00002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16372821/&quot;>https://pubmed.ncbi.nlm.nih.gov/16372821</a></p></li><li><p>Scott, LJ (2015). Teneligliptin: a review in type 2 diabetes. <i>Clinical drug investigation</i> 35(11) 765–772. DOI:<a href=&quot;https://doi.org/10.1007/s40261-015-0348-9&quot;>10.1007/s40261-015-0348-9</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26475720/&quot;>https://pubmed.ncbi.nlm.nih.gov/26475720</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end GlimepirideAndPioglitazone;
